title: Glycoengineering of alphaGal xenoantigen on recombinant peptide bearing the J28 pancreatic oncofetal glycotope.
abstract: In human pancreatic adenocarcinoma, alterations of glycosylation processes leads to the expression of tumor-associated carbohydrate antigens, representing potential targets for cancer immunotherapy. Among these pancreatic tumor-associated carbohydrate antigens, the J28 glycotope located within the O-glycosylated mucin-like C-terminal domain of the fetoacinar pancreatic protein (FAPP) and expressed at the surface of human tumoral tissues, can be a good target for anticancer therapeutic vaccines. However, the oncodevelopmental self character of the J28 glycotope associated with the low immunogenicity of tumor-associated carbohydrate antigens may be a major obstacle to effective anti-tumor vaccine therapy. In this study, we have investigated a method to increase the immunogenicity of the recombinant pancreatic oncofetal J28 glycotope by glycoengineering Galalpha1,3Galss1,4GlcNAc-R (alphaGal epitope) which may be recognized by natural anti-alphaGal antibody present in humans. For this purpose, we have developed a stable Chinese hamster ovary cell clone expressing the alphaGal epitope by transfecting the cDNA encoding the alpha1,3galactosyltransferase. These cells have been previously equipped to produce the recombinant O-glycosylated C-terminal domain of FAPP carrying the J28 glycotope. As a consequence, the C-terminal domain of FAPP produced by these cells carries the alphaGal epitope on oligosaccharide structures associated with the J28 glycotope. Furthermore, we show that this recombinant "alpha1,3galactosyl and J28 glycotope" may not only be targeted by human natural anti-alphaGal antibodies but also by the mAbJ28, suggesting that the J28 glycotope remains accessible to the immune system as vaccinating agent. This approach may be used for many identified tumor-associated carbohydrate antigens which can be glycoengineered to carry a alphaGal epitope to increase their immunogenicity and to develop therapeutic vaccines.
authors: INSERM UMR-777, Faculté de Médecine-Timone, 27 Boulevard Jean Moulin, 13385 Marseille Cedex 05, France.
authors: Marie-Odile
authors: MO
authors: Sadoulet
authors: Cécile
authors: C
authors: Franceschi
authors: Muriel
authors: M
authors: Aubert
authors: Françoise
authors: F
authors: Silvy
authors: Jean-Paul
authors: JP
authors: Bernard
authors: Dominique
authors: D
authors: Lombardo
authors: Eric
authors: E
authors: Mas
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000201:enzymology / Q000276:immunology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D015478:Antigens, Heterophile / Q000737:chemistry* / Q000235:genetics / Q000276:immunology; D000951:Antigens, Neoplasm / Q000737:chemistry* / Q000276:immunology; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000737:chemistry / Q000276:immunology; D016466:CHO Cells; D002999:Clone Cells; D006224:Cricetinae; D003412:Cricetulus; D018076:DNA, Complementary; D000939:Epitopes / Q000737:chemistry* / Q000276:immunology; D005700:Galactosyltransferases / Q000235:genetics / Q000276:immunology; D006023:Glycoproteins / Q000737:chemistry*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000201:enzymology / Q000276:immunology; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000737:chemistry / Q000276:immunology; D014162:Transfection
chemical_list: D000911:Antibodies, Monoclonal; D015478:Antigens, Heterophile; D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D018076:DNA, Complementary; D000939:Epitopes; D006023:Glycoproteins; D011994:Recombinant Proteins; D005700:Galactosyltransferases